1. Home
  2. ICCC vs PLUR Comparison

ICCC vs PLUR Comparison

Compare ICCC & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICCC
  • PLUR
  • Stock Information
  • Founded
  • ICCC 1982
  • PLUR 2001
  • Country
  • ICCC United States
  • PLUR Israel
  • Employees
  • ICCC N/A
  • PLUR N/A
  • Industry
  • ICCC Biotechnology: Pharmaceutical Preparations
  • PLUR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ICCC Health Care
  • PLUR Health Care
  • Exchange
  • ICCC Nasdaq
  • PLUR Nasdaq
  • Market Cap
  • ICCC 35.4M
  • PLUR 30.2M
  • IPO Year
  • ICCC 1987
  • PLUR N/A
  • Fundamental
  • Price
  • ICCC $4.15
  • PLUR $5.70
  • Analyst Decision
  • ICCC
  • PLUR
  • Analyst Count
  • ICCC 0
  • PLUR 0
  • Target Price
  • ICCC N/A
  • PLUR N/A
  • AVG Volume (30 Days)
  • ICCC 6.3K
  • PLUR 6.0K
  • Earning Date
  • ICCC 08-08-2024
  • PLUR 09-10-2024
  • Dividend Yield
  • ICCC N/A
  • PLUR N/A
  • EPS Growth
  • ICCC N/A
  • PLUR N/A
  • EPS
  • ICCC N/A
  • PLUR N/A
  • Revenue
  • ICCC $21,282,719.00
  • PLUR $341,000.00
  • Revenue This Year
  • ICCC N/A
  • PLUR N/A
  • Revenue Next Year
  • ICCC N/A
  • PLUR N/A
  • P/E Ratio
  • ICCC N/A
  • PLUR N/A
  • Revenue Growth
  • ICCC 32.89
  • PLUR 93.75
  • 52 Week Low
  • ICCC $4.05
  • PLUR $3.44
  • 52 Week High
  • ICCC $5.69
  • PLUR $8.48
  • Technical
  • Relative Strength Index (RSI)
  • ICCC 42.18
  • PLUR 51.43
  • Support Level
  • ICCC $4.10
  • PLUR $5.36
  • Resistance Level
  • ICCC $4.29
  • PLUR $5.81
  • Average True Range (ATR)
  • ICCC 0.10
  • PLUR 0.33
  • MACD
  • ICCC -0.00
  • PLUR 0.00
  • Stochastic Oscillator
  • ICCC 40.00
  • PLUR 48.00

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

About PLUR Pluri Inc.

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.

Share on Social Networks: